Drug Trial Radar · NCT03066219
Safety and Efficacy of BRM421 for Dry Eye Syndrome
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
157
Actual
Start
Feb 7, 2017
Primary completion
May 20, 2017
Study completion Jun 28, 2017
Sponsor
- Lead sponsor
- BRIM Biotechnology Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
Conditions
- Dry Eye Syndrome
Interventions
BRM421Drug
0.03%(w/v) BRIM421 ophthalmic solution
PlaceboDrug
vehicle ophthalmic drops
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sign: Corneal Fluorescein Staining ScoreTime frame: change from baseline to week 4
- Symptom: Ocular Discomfort ScoreTime frame: change from baseline to week 4
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Central Maine Eye Care
Lewiston, Maine
Andover Eye Associates
Andover, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.